Immutep’s experimental immunotherapy, IMP761, continues to demonstrate a favorable safety profile, along with sustained suppression of T-cell activity, immune cells that are overly active in multiple sclerosis (MS) and other autoimmune diseases. These findings are based on data from healthy people enrolled in an ongoing first-in-human Phase 1 trial (NCT06637865), who received single doses of IMP761 […]
The post Experimental MS therapy reinforces ‘brakes’ on overactive T-cells appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com